GLP1R and type 2 diabetes mellitus: In terms of T2DM therapy, the currently recommended sodium-glucose cotransporter inhibitors, or glucagon-like peptide-1 receptor antagonists, which may influence the risk of long term adverse events [42], were not used in the study group at the time of patient recruitment.